DeuterOncology's CMO, Prof Jaap Verweij will be giving a talk today at the 27th Annual JFCR-ISCC Symposium today. His talk entitled 'Developing a novel TKI for a rare indication in a crowded market, DO-2 as example' will showcase our pre-clinical and emerging clinical data that differentiates DO-2 as a potential best in class MET inhibitor that thus far has resulted in minimal side effects at doses that result in tumour volume reduction.
DeuterOncology NV
Biotechnology Research
Liège, Walloon Region 305 followers
Developing deuterated BEST in CLASS MET kinase Inhibitor
About us
DeuterOncology NV is a Liege based clinical stage biotechnology company that was founded in September 2020 by Dr Timothy Perera. The company is currently focused on the clinical development of a highly selective brain penetrant, deuterated MET kinase inhibitor DO-2.
- Website
-
www.deuteroncology.com
External link for DeuterOncology NV
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Headquarters
- Liège, Walloon Region
- Type
- Privately Held
- Founded
- 2020
- Specialties
- Drug Development, Deuterated small molecules, and MET kinase inhibitor
Locations
-
Primary
Get directions
Clos Chanmurly 13
Liège, Walloon Region 4000, BE